Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC 5 dagen ago0OpmerkingenEN NLRead More
Informatiedocument Nieuwe Aandelen – 07 november 2025 november 9, 20250OpmerkingenInformatie betreffende de toelating tot notering en handel op de gereglementeerde markt van Euronext Brussel van 1.000.000.000 nieuwe aandelenRead More
New Shares Information Document – 07 November 2025 november 9, 20250OpmerkingenInformation regarding the admission to listing and trading on the regulated market of euronext brussels of 1,000,000,00 new sharesRead More
Oxurion ends discussions regarding previously announced preclinical transaction and continues integration of a strategic clinical partner november 3, 20250OpmerkingenEN NL FRRead More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC oktober 23, 20250OpmerkingenEN NLRead More
Oxurion Receives Amended Transparency Notifications from Atlas Special Opportunities II LLC oktober 17, 20250OpmerkingenEN NLRead More
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC oktober 16, 20250OpmerkingenEN NLRead More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas oktober 15, 20250OpmerkingenEN NLRead More
Oxurion signs letter of intent for the contemplated acquisition of a CRO with strong complementarity to Axiodis oktober 13, 20250OpmerkingenEN NL FRRead More
Oxurion provides an update related to its investment strategy in digital assets oktober 9, 20250OpmerkingenEN NL FR Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas oktober 3, 20250OpmerkingenEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC oktober 2, 20250OpmerkingenEN NL Read More
Tussentijdse halfjaarresultaten 30 juni 2025 september 30, 20250OpmerkingenTussentijdse halfjaarresultaten 30 juni 2025Read More
Interim Financial Report Half-year results as of June 30, 2025 september 30, 20250OpmerkingenInterim Financial Report Half-year results as of June 30, 2025Read More
Axiodis CRO, the French subsidiary of the Oxurion Group, announces a dual AI-driven strategic initiative to transform clinical trials september 16, 20250OpmerkingenEN NL FRRead More
Eerste aanvulling op het prospectus van 15 oktober 2024 september 10, 20250OpmerkingenEerste aanvulling op het prospectus van 15 oktober 2024Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC september 8, 20250OpmerkingenEN NL Read More
Oxurion confirms progress in negotiations related to its treasury diversification strategy; closing of the transaction expected before September 25, 2025 september 1, 20250OpmerkingenEN NL FRRead More
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC september 1, 20250OpmerkingenEN NLRead More
